PF exhibited selective anti-cancer activity in CDX2-low CRC PDOs (as determined based on a threshold that was determined using StepMiner81 cutoff; see STAR Methods), reflected by low IC50 values. This evidence concerns the gene CDX2 and colorectal carcinoma.